Stock Taper
No price history available for SRZNW over this range.
Surrozen, Inc. is a biotech firm developing tissue-specific antibodies to modulate the Wnt pathway for regenerative therapies across various organs and diseases.

SZN-8141 is a clinical-stage bifunctional antibody targeting retinal diseases like wet AMD and DME by activating the Wnt pathway and inhibiting VEGF, focusing on ophthalmology.
| Icon | PRODUCT | Q3-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|
![]() | Collaboration and license revenue | $0 | $5M ▲ | $5M |
| Map | REGION | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | GERMANY | — | — | $5M | $5M |
![]() | UNITED STATES | $1M | $500K ▼ | — | — |
| PEER | PRICE | |
|---|---|---|
KTTA | $0.56 | COMPARE |
REVB | $1.05 | COMPARE |
CERO | $0.01 | COMPARE |
NKGN | $0.00 | COMPARE |
VINC | $0.01 | COMPARE |
SYRS | $0.00 | COMPARE |
MSPR | $0.00 | COMPARE |
VRPX | $0.00 | COMPARE |